Filing Flows › BioNexus Gene Lab (BGLC) › Q4 2025
BioNexus Gene Lab (BGLC) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Apr 14, 2026
BioNexus Gene Lab (BGLC) reported revenue of $484K for the fourth quarter 2025 (Q4 2025), -81% from a year earlier and -81% from the quarter before. Operating margin was -213.5%, net loss $1.0M (214.2% of revenue).
BioNexus Gene Lab, Q4 2025: revenue $484K (-81% year over year), operating margin -213.5%, net loss $1.0M, operating cash flow $961K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $484K | -81% | -81% |
| Operating profit | −$1.0M | — | — |
| Net earnings | −$1.0M | — | -397% |
| Operating cash flow | $961K | — | +338% |
| Free cash flow | $960K | — | +346% |
What changed
Revenue was $484K in Q4 2025, down 81% year over year and down 81% from the previous quarter.
Operating costs exceeded revenue by $1.0M, an operating margin of -213.5%. The fastest-growing cost line was Other operating costs (+1595%). The quarter ended with a net loss of $1.0M, wider than the previous quarter's $709K loss.
Operating cash flow was $1.0M (up 338% year over year). Non-cash charges added back $28K of depreciation and $795K of share-based compensation. Working capital and other items added $1.2M. Capital expenditures of $1K left free cash flow of $1.0M.
Questions
What was BioNexus Gene Lab's revenue in the fourth quarter 2025?
BioNexus Gene Lab (BGLC) reported revenue of $484K for the fourth quarter 2025 (Q4 2025), -81% from a year earlier and -81% from the quarter before.
Was BioNexus Gene Lab profitable in the fourth quarter 2025?
Operating loss was $1.0M (-213.5% of revenue) and net loss $1.0M.
Source: BioNexus Gene Lab 10-K on SEC EDGAR.